Skip to content
DataLookout
Menu

NALVANCANCT07636655

Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 8 words
    • Primary and study completion pushed from Sep 1, 2051 to Dec 1, 2051
  2. Notable Start date: Jun 1, 2026 to Sep 1, 2026
    • Primary and study completion pushed from Jun 1, 2051 to Sep 1, 2051
    v3
  3. Minor Secondary endpoints: 1 to 3v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Identification of a CD8+ T-cell signature sensitive to B-cell depletion.
Timeframe: From diagnosis up to 2 years after the final rituximab infusion

Secondary (3)

To characterize the relationship between B-cell immune responses and CD8 T-cell responses in patients with ANCA-associated vasculitis.
To identify potential immune biomarkers associated with disease phenotype and outcomes, including CD4 T-cell subsets, regulatory T cells (Tregs), innate lymphoid cells, immunoglobulins, and inflammatory markers.
To evaluate the association between lymphocyte-related immune biomarkers and the occurrence of intercurrent clinical events, including infectious and cardiovascular complications.

Arms and interventions

NALVANCA Cohort - ANCA-associated vasculitis patients treated with Rituximab.

This cohort follows adult patients with ANCA-associated vasculitis, a systemic autoimmune disease. The intervention of interest is Rituximab (RTX) therapy, used to induce B-cell depletion. The study involves longitudinal monitoring with the systematic collection of biological samples at key time points: before treatment induction, during the depletion phase, and upon immune reconstitution (2 years after the last injection or at relapse). The objective is to study the pleiotropic effects of B-cell depletion on CD8+ T-cells to identify biomarkers capable of predicting the risk of relapse.

Other: systematic collection of additional biological samples (blood volume)

Diagnostic tests: BVAS (Birmingham Vasculitis Activity Score) and VDI (Vasculitis Damage Index)

Sites

1 site in 1 country

  • CHU de NantesNantes, Loire-atlantique, France